Fibroblast Growth Factor Receptor (FGFR)
FGFR inhibitors are targeted therapies that block the activity of fibroblast growth factor receptors (FGFRs), which are involved in cell proliferation, differentiation, and angiogenesis. FGFR signaling contributes to the formation of new blood vessels in tumors, promoting their growth and survival. Inhibiting FGFR can therefore reduce angiogenesis and tumor progression. At CymitQuimica, we provide a range of high-quality FGFR inhibitors to support your research in cancer, developmental biology, and angiogenesis.
Found 177 products of "Fibroblast Growth Factor Receptor (FGFR)"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Nintedanib esylate
CAS:Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/βFormula:C31H33N5O4·C2H6O3SPurity:99.43% - 99.98%Color and Shape:SolidMolecular weight:649.76GW786034B
CAS:Pazopanib HCl (Votrient) inhibits VEGFR1-3, PDGFR, FGFR, c-Kit, c-Fms with IC50 range 10-146 nM in cell-free assays.Formula:C21H23N7O2S·HClPurity:99.87%Color and Shape:SolidMolecular weight:473.98Ref: TM-T6930
10mg44.00€25mg70.00€50mg96.00€100mg140.00€200mg229.00€500mg329.00€1mL*10mM (DMSO)34.00€KW-2449
CAS:KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Formula:C20H20N4OPurity:98.43% - 99.69%Color and Shape:SolidMolecular weight:332.4PRN1371
CAS:PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).Formula:C26H30Cl2N6O4Purity:98.65%Color and Shape:SolidMolecular weight:561.46Ref: TM-TQ0015
1mg77.00€2mg100.00€5mg166.00€10mg289.00€25mg492.00€50mg710.00€100mg973.00€1mL*10mM (DMSO)200.00€Alofanib
CAS:Alofanib (RPT835) selectively inhibits FGFR2 in KATO III cells with IC50 <10 nM; doesn’t affect FGFR1/3 or FGF2-FGFR2 binding.Formula:C19H15N3O6SPurity:99.53% - 99.81%Color and Shape:SolidMolecular weight:413.4R1530
CAS:R1530 is a multikinase inhibitor with antineoplastic and antiangiogenesis activities.Formula:C18H14ClFN4OPurity:98.422%Color and Shape:SolidMolecular weight:356.78Ref: TM-TQ0317
1mg39.00€2mg52.00€5mg84.00€10mg130.00€25mg264.00€50mg423.00€100mg640.00€1mL*10mM (DMSO)93.00€TG 100801
CAS:TG 100801 is a dual inhibitor of VEGFr2 and Src family kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).Formula:C33H30ClN5O3Purity:99.28% - 99.61%Color and Shape:SolidMolecular weight:580.08FGFR2-IN-3
CAS:FGFR2-IN-3 is an orally active selective FGFR2 inhibitor[1].
Formula:C28H24FN7O2Purity:99.63%Color and Shape:SoildMolecular weight:509.53FGFR-IN-13
CAS:FGFR-IN-13 (compound III-30), an irreversible covalent inhibitor of the fibroblast growth factor receptor (FGFR), effectively modulates signaling through FGFR1 (IC 50 = 0.20 ± 0.02 nM) and FGFR4 (IC 50 = 0.40 ± 0.03 nM). It suppresses the expression of crucial proteins such as total-PARP and Bcl-2, while enhancing the expression of Cleaved-PARP and Bax in a dose-dependent manner. Notably, FGFR-IN-13 demonstrates considerable antitumor and oral activity [1].Formula:C23H21N5O3Molecular weight:415.44FGFR2-IN-2
CAS:FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.Formula:C23H22N4OPurity:98.09%Color and Shape:SolidMolecular weight:370.45FGFR3-IN-2
CAS:FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor that inhibits FGFR3 (IC50: 4.1 nM) and VEGFR2 (IC50: 570 nM).Formula:C28H39N9O4SColor and Shape:SolidMolecular weight:597.73ARQ 069
CAS:ARQ 069 inhibits FGFR2 phosphorylation concentration-dependently (IC50: 9.7 µM), without affecting β-actin. Preferentially binds inactive FGFR1/2.Formula:C18H15N3Purity:98%Color and Shape:SolidMolecular weight:273.33MAX-40279 hemifumarate
CAS:MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.Formula:C48H50F2N12O6S2Color and Shape:SolidMolecular weight:993.12TG 100801 Hydrochloride
CAS:TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.Formula:C33H31Cl2N5O3Purity:98%Color and Shape:SolidMolecular weight:616.54SSR128129E free acid
CAS:SSR128129E free acid is an orally available and allosteric inhibitor of FGFR(IC50 of 1.9 μM for FGFR1).Formula:C18H16N2O4Purity:98%Color and Shape:SolidMolecular weight:324.33TG 100572
CAS:TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2Formula:C26H26ClN5O2Purity:98%Color and Shape:SolidMolecular weight:475.97MAX-40279 hemiadipate
CAS:MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)Formula:C50H56F2N12O6S2Color and Shape:SolidMolecular weight:1023.19MAX-40279
CAS:MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.Formula:C22H23FN6OSColor and Shape:SolidMolecular weight:438.52FGFR4-IN-5
CAS:FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.Formula:C23H23Cl2N5O5Color and Shape:SolidMolecular weight:520.37CPL304110
CAS:CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54
